CHICAGO/TOKYO: Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and blow to Biogen, which lost more than US$18 billion of its value on Thursday.
Markets in Japan were closed for a national holiday so the impact of the news on Eisai will be delayed. Abrahams, who reduced his Biogen price target to US$240 per share, said further declines were likely given that"investors owned Biogen to not miss out on what could have been one of the biggest blockbuster products in the pipeline of large biopharma."Any successful treatment for Alzheimer's, which affects about 5.7 million Americans, is virtually guaranteed to become one of the world's top-selling drugs.
Source: News Formal (newsformal.com)
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Biogen, Eisai scrap Alzheimer drug trialsBiogen Inc and Eisai Co Ltd said on Thursday they will discontinue two late-stage trials testing an experimental treatment for Alzheimer's disease.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Biogen scraps Alzheimer drug trials, wiping US$17 billion off its market valueBiogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer's drug, they said Thursday, marking the latest setback for ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Biogen scraps Alzheimer drug trials, shares slump by a quarterBiogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer's drug, they said Thursday, marking the latest setback for ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Biogen scraps Alzheimer's trial, shares skidBiogen Inc and Eisai Co Ltd said on Thursday they will discontinue two late-stage trials testing an experimental treatment for Alzheimer's disease.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Biogen scraps Alzheimer drug trials, wiping US$17 billion off its market valueBiogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer's drug, they said Thursday, marking the latest setback for ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Biogen, Eisai scrap Alzheimer drug trialsBiogen Inc and Eisai Co Ltd said on Thursday they will discontinue two late-stage trials testing an experimental treatment for Alzheimer's disease.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Biogen scraps Alzheimer drug trials, shares slump by a quarterBiogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer's drug, they said Thursday, marking the latest setback for ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Biogen scraps Alzheimer's trial, shares skidBiogen Inc and Eisai Co Ltd said on Thursday they will discontinue two late-stage trials testing an experimental treatment for Alzheimer's disease.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Buffett's Berkshire says vice chairmen Jain, Abel each make US$18 million[NEW YORK] Berkshire Hathaway Inc on Friday said its newest vice chairmen, Greg Abel and Ajit Jain, were each awarded about US$18 million last year, in the first detailed look at the pay of the men considered the leading candidates to succeed Warren Buffett as the conglomerate's chief executive. Read more at The Business Times.
Source: BusinessTimes - 🏆 15. / 51 Read more »